Platelet glycoprotein Ib alpha fusion polypeptides and methods of use thereof
The present invention provides compositions and methods for treating or preventing vascular-associated disorders.
1 - 28 . (canceled)
29 . A method of inhibiting adherence of a platelet to von Willebrand Factor in a subject, the method comprising administering to a subject in need thereof a polypeptide comprising the amino acid sequence of SEQ ID NO:5 in an amount sufficient to inhibit adherence of said platelet to von Willebrand Factor.
30 - 46 . (canceled)
47 . A method of treating a disorder associated with platelet activation in a subject, the method comprising administering to a subject in need thereof a polypeptide comprising the amino acid sequence of SEQ ID NO:5.
48 . The method of claim 47 , wherein said disorder is associated with thrombotic disease.
49 . The method of claim 47 , wherein said disorder is ischemic heart disease, angina, acute myocardial infarction, stroke, venous thrombosis, atherosclerosis, restenosis, vascular inflammation or arterial thrombosis.
50 . The method of claim 47 , wherein said disorder is angina.
51 . The method of claim 50 , wherein said angina is unstable angina.
52 . The method of claim 47 , wherein said subject is a human.
53 . The method of claim 47 , further comprising administering to said subject a compound selected from the group consisting of acetylsalicylic acid, heparin, a glycoprotein IIb/IIIa antagonist, clopidogrel, a P-selectin antagonist, a thrombin inhibitor and a thrombolytic enzyme.
54 . The method of claim 47 , wherein said disorder is ischemic heart disease.
55 . The method of claim 47 , wherein said disorder is acute myocardial infarction.
56 . The method of claim 47 , wherein said disorder is stroke.
57 . The method of claim 47 , wherein said disorder is venous thrombosis.
58 . The method of claim 47 , wherein said disorder is atherosclerosis.
59 . The method of claim 47 , wherein said disorder is arterial thrombosis.
60 . The method of claim 47 , wherein said disorder is restenosis.
61 . The method of claim 60 , wherein said restenosis is angioplasty-related restenosis.
62 . The method of claim 50 , wherein said angina is stable angina.
63 . The method of claim 47 , wherein said disorder is vascular inflammation.
64 . The method of claim 47 , further comprising administering to said subject acetylsalicylic acid.
65 . The method of claim 47 , further comprising administering to said subject heparin.
66 . The method of claim 47 , further comprising administering to said subject a glycoprotein IIb/IIIa antagonist.
67 . The method of claim 47 , further comprising administering to said subject clopidogrel.
68 . The method of claim 47 , further comprising administering to said subject a P-selectin antagonist.
69 . The method of claim 47 , further comprising administering to said subject a thrombin inhibitor.
70 . The method of claim 47 , further comprising administering to said subject a thrombolytic enzyme.
71 . The method of claim 29 , wherein said subject is a human.
72 . The method of claim 29 , wherein said subject is a primate.
73 . The method of claim 47 , wherein said subject is a primate.
74 . The method of claim 47 , wherein said polypeptide is a multimeric polypeptide.
75 . The method of claim 74 , wherein said multimeric polypeptide is a dimer.
76 . The method of claim 47 , wherein said polypeptide consists essentially of the amino acid sequence of SEQ ID NO:5.
77 . The method of claim 47 , wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:5.
78 . A method of inhibiting adherence of a platelet to von Willebrand Factor in a human, the method comprising administering to a human in need thereof a polypeptide that consists of the amino acid sequence of SEQ ID NO:5, wherein the polypeptide blocks von Willebrand Factor binding sites preventing platelet adherence whereby allowing for a reduced amount of restrained blood flow.